Quick Answer
Tesamorelin before-and-after results are best understood through visceral fat, waist profile, and abdominal-body-composition changes. The most important study reported a 10.9% reduction in visceral adipose tissue at six months with tesamorelin compared with 0.6% with placebo. People continuing treatment in the extension data had about an 18% visceral-fat reduction over 12 months.
That is the real promise: a leaner abdominal profile driven by deeper visceral-fat change, not a fake overnight transformation.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileWhat Changes First
Tesamorelin is not a stimulant fat burner, and it is not a GLP-1 appetite drug. The before-and-after story should be measured in months because the clinical trials measured body-composition change over 26 weeks and beyond.
Early subjective changes may vary, but the evidence-backed milestones are longer term: visceral-fat reduction, waist-circumference improvement, waist-to-hip ratio improvement, and better belly-profile ratings in the studied population.
The Six-Month Result
The landmark randomized study followed adults with HIV and central fat accumulation. After six months, the tesamorelin group had a 10.9% reduction in visceral adipose tissue. Placebo had a 0.6% reduction. The trial also reported improvements in trunk fat, waist circumference, waist-to-hip ratio, patient-rated belly appearance distress, and physician-rated belly profile.
That combination is why tesamorelin has such a strong body-composition reputation. The results were not limited to a lab marker. Imaging, waist metrics, and visible abdominal-profile ratings all moved in the right direction.
| Timeline | What studies suggest |
|---|---|
| Early weeks | Mechanism is active, but visible abdominal change may not be obvious yet. |
| Around six months | Major trial data show meaningful visceral-fat and waist-profile changes. |
| Around 12 months | Continued treatment data showed sustained VAT reduction near 18%. |
| After stopping | Visceral fat reaccumulated in extension data after discontinuation. |
What A Good Before-And-After Should Show
A useful tesamorelin before-and-after should focus on the waist and abdominal profile, not just body weight. Scale weight can miss the point because EGRIFTA SV is described in the label as weight neutral and not indicated for weight-loss management.
That can sound counterintuitive, but it makes sense. If the main change is visceral fat, the mirror, waist measurement, and imaging may tell a more useful story than the scale alone.
Liver Fat And Internal Change
The 2014 randomized clinical trial added another layer by studying liver fat. In that study, tesamorelin reduced both visceral adipose tissue and liver fat compared with placebo over six months.
For before-and-after expectations, this is important because the most meaningful changes may not be fully visible. A person can care about the way the abdomen looks while the research is also pointing to deeper compartments that require imaging to measure.
Results In More Current HIV Treatment Context
The 2024 analysis in people with HIV on integrase-inhibitor regimens makes the tesamorelin results story more current. In that analysis, tesamorelin led to significant declines in visceral fat, hepatic fat, and trunk-to-appendicular fat ratio compared with placebo, with no exacerbation of glycemic control.
That matters because antiretroviral treatment has changed since the original Phase 3 era. Tesamorelin still produced favorable body-composition signals in a newer treatment context.
Why Results Can Recede After Stopping
One of the most useful findings from the extension data is that visceral fat reaccumulated after tesamorelin was stopped. This is not a failure of the compound. It tells readers something honest and important: tesamorelin's body-composition effect appears tied to continued treatment exposure.
That makes expectations more realistic. Tesamorelin is powerful because it has a measurable effect while active. It should not be framed as a permanent one-cycle fix.
Why Product Clarity Matters For Results
Before-and-after expectations depend on the compound being what the label says it is. For research listings, the basics matter: visible vial amount, clear product name, documentation signal, and a vendor profile that is not vague.
Tesamorelin Vendors With Documentation Signals
View all Tesamorelin vendors| Vendor | Country | COAs | Rating | Reviews | Notes | Website |
|---|---|---|---|---|---|---|
| LA Peptides | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| NextGenPeps | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| Alpha Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Ascension Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| BioCollex | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Coastal Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
FAQ
What does tesamorelin before and after usually show?
The strongest expectation is a change in waist profile and visceral abdominal fat over months.
Does tesamorelin work fast?
Tesamorelin is better viewed as a months-long body-composition peptide than a fast cosmetic fix.
Are tesamorelin results mostly scale weight?
No. The most important data are about visceral fat and waist-related body-composition measures.
Can tesamorelin results disappear?
In extension data, visceral fat reaccumulated after discontinuation, so continued exposure appeared important for maintaining the effect.